newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update

CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment